BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998;77:448-55. [PMID: 9472642 DOI: 10.1038/bjc.1998.71] [Cited by in Crossref: 140] [Cited by in F6Publishing: 133] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Chang T, Huang Y, Ou Y. The role of ginsenosides in inhibiting ubiquitin activating enzyme (E1) activity. Journal of Functional Foods 2014;7:462-70. [DOI: 10.1016/j.jff.2014.01.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Wu XR, Sha JJ, Liu DM, Chen YH, Yang GL, Zhang J, Chen YY, Bo JJ, Huang YR. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma. Eur J Surg Oncol 2013;39:100-6. [PMID: 23102595 DOI: 10.1016/j.ejso.2012.10.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
3 O’connor OA. The emerging role of bortezomib in the treatment of indolent non-hodgkin’ and mantle cell lymphomas. Curr Treat Options in Oncol 2004;5:269-81. [DOI: 10.1007/s11864-004-0018-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
4 Ramos-vara JA, Miller MA. Immunohistochemical Detection of Protein Gene Product 9.5 (PGP 9.5) in Canine Epitheliotropic T-Cell Lymphoma (Mycosis Fungoides). Vet Pathol 2007;44:74-9. [DOI: 10.1354/vp.44-1-74] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
5 Neznanov N, Dragunsky EM, Chumakov KM, Neznanova L, Wek RC, Gudkov AV, Banerjee AK. Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS One 2008;3:e1887. [PMID: 18382670 DOI: 10.1371/journal.pone.0001887] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
6 Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC. Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002;21:1346-58. [DOI: 10.1038/sj.onc.1205205] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 6.2] [Reference Citation Analysis]
7 Asai A, Tsujita T, Sharma SV, Yamashita Y, Akinaga S, Funakoshi M, Kobayashi H, Mizukami T. A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Biochem Pharmacol 2004;67:227-34. [PMID: 14698035 DOI: 10.1016/j.bcp.2003.08.035] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
8 Ohtani M, Isozaki H, Fujii K, Nomura E, Niki M, Mabuchi H, Nishiguchi K, Toyoda M, Ishibashi T, Tanigawa N. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-Early stage gastric carcinoma. Cancer 1999;85:1711-8. [DOI: 10.1002/(sici)1097-0142(19990415)85:8<1711::aid-cncr10>3.0.co;2-l] [Cited by in Crossref: 43] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chain DG, Schwartz JH, Hegde AN. Ubiquitin-mediated proteolysis in learning and memory. Mol Neurobiol 1999;20:125-42. [DOI: 10.1007/bf02742438] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
10 Subramanian B, Nakeff A, Media J, Wentland M, Valeriote F. Cellular drug action profile paradigm applied to XK469: Mechanism of action paradigm. Journal of Experimental Therapeutics and Oncology 2002;2:253-63. [DOI: 10.1046/j.1359-4117.2002.01040.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
11 Luogen C, Shuzhen W, Zhihao C, Zhongying L. cDNA representational difference analysis of the deltamelthrin-resistant and -susceptible populations in diamondback moth (Plutella xylostella L.). J Appl Entomology 2005;129:515-20. [DOI: 10.1111/j.1439-0418.2005.01007.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Groll M, Kim KB, Kairies N, Huber R, Crews CM. Crystal Structure of Epoxomicin:20S Proteasome Reveals a Molecular Basis for Selectivity of α‘,β‘-Epoxyketone Proteasome Inhibitors. J Am Chem Soc 2000;122:1237-8. [DOI: 10.1021/ja993588m] [Cited by in Crossref: 249] [Cited by in F6Publishing: 146] [Article Influence: 11.9] [Reference Citation Analysis]
13 Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 2003;101:3606-14. [DOI: 10.1182/blood-2002-10-3146] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
14 Masdehors P, Merle-béral H, Maloum K, Ömura S, Magdelénat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000;96:269-74. [DOI: 10.1182/blood.v96.1.269.013k10_269_274] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Dui W, Lu W, Ma J, Jiao R. A Systematic Phenotypic Screen of F-box Genes Through a Tissue-specific RNAi-based Approach in Drosophila. Journal of Genetics and Genomics 2012;39:397-413. [DOI: 10.1016/j.jgg.2012.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
16 Bryan L, Clynes M, Meleady P. The emerging role of cellular post-translational modifications in modulating growth and productivity of recombinant Chinese hamster ovary cells. Biotechnol Adv 2021;49:107757. [PMID: 33895332 DOI: 10.1016/j.biotechadv.2021.107757] [Reference Citation Analysis]
17 Cui Z, Gilda JE, Gomes AV. Crude and purified proteasome activity assays are affected by type of microplate. Anal Biochem 2014;446:44-52. [PMID: 24141075 DOI: 10.1016/j.ab.2013.10.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
18 Kumar S, Harmanci A, Vytheeswaran J, Gerstein MB. SVFX: a machine learning framework to quantify the pathogenicity of structural variants. Genome Biol 2020;21:274. [PMID: 33168059 DOI: 10.1186/s13059-020-02178-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
19 Sun X, Wei L, Lidén J, Hui G, Dahlman-wright K, Hjerpe A, Dobra K. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 2005;207:91-101. [DOI: 10.1002/path.1810] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
20 Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol. 2002;198:142-156. [PMID: 12237873 DOI: 10.1002/path.1121] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 6.0] [Reference Citation Analysis]
21 Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 1999;96:10403-8. [PMID: 10468620 DOI: 10.1073/pnas.96.18.10403] [Cited by in Crossref: 714] [Cited by in F6Publishing: 682] [Article Influence: 32.5] [Reference Citation Analysis]
22 Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 2008;111:5068-77. [PMID: 18334673 DOI: 10.1182/blood-2007-09-115170] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 6.4] [Reference Citation Analysis]
23 Kalish RS, Askenase PW. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999;103:192-9. [PMID: 9949307 DOI: 10.1016/s0091-6749(99)70489-6] [Cited by in Crossref: 95] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
24 Piccinini M, Tazartes O, Mezzatesta C, Ricotti E, Bedino S, Grosso F, Dianzani U, Tovo PA, Mostert M, Musso A, Rinaudo MT. Proteasomes are a target of the anti-tumour drug vinblastine. Biochem J 2001;356:835-41. [PMID: 11389692 DOI: 10.1042/0264-6021:3560835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
25 Chou C, Yung BY, Hsu C. Involvement of nPKC-MAPK pathway in the decrease of nucleophosmin/B23 during megakaryocytic differentiation of human myelogenous leukemia K562 cells. Life Sciences 2007;80:2051-9. [DOI: 10.1016/j.lfs.2007.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
26 Yadav D, Mishra BN, Khan F. Quantitative structure-activity relationship and molecular docking studies on human proteasome inhibitors for anticancer activity targeting NF-κB signaling pathway. J Biomol Struct Dyn 2020;38:3621-32. [PMID: 31514715 DOI: 10.1080/07391102.2019.1666743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Jeon HB, Choi ES, Yoon JH, Hwang JH, Chang JW, Lee EK, Choi HW, Park ZY, Yoo YJ. A proteomics approach to identify the ubiquitinated proteins in mouse heart. Biochem Biophys Res Commun 2007;357:731-6. [PMID: 17451654 DOI: 10.1016/j.bbrc.2007.04.015] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
28 Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862-871. [PMID: 12415256 DOI: 10.1038/nrc927] [Cited by in Crossref: 599] [Cited by in F6Publishing: 535] [Article Influence: 31.5] [Reference Citation Analysis]
29 Murray RZ, Norbury C. Proteasome inhibitors as anti-cancer agents: . Anti-Cancer Drugs 2000;11:407-17. [DOI: 10.1097/00001813-200007000-00001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
30 Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A 2000;97:1032-7. [PMID: 10655479 DOI: 10.1073/pnas.97.3.1032] [Cited by in Crossref: 314] [Cited by in F6Publishing: 311] [Article Influence: 15.0] [Reference Citation Analysis]
31 Arlt A, Minkenberg J, Kruse ML, Grohmann F, Fölsch UR, Schäfer H. Immediate early gene-X1 interferes with 26 S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2. Biochem J 2007;402:367-75. [PMID: 17107344 DOI: 10.1042/BJ20061072] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
32 Ishibashi Y, Hanyu N, Suzuki Y, Yanai S, Tashiro K, Usuba T, Iwabuchi S, Takahashi T, Takada K, Ohkawa K, Urashima M, Yanaga K. Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. Cancer Lett 2004;211:111-7. [PMID: 15194223 DOI: 10.1016/j.canlet.2004.01.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
33 Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem. 2001;276:44641-44646. [PMID: 11572859 DOI: 10.1074/jbc.m105170200] [Cited by in Crossref: 178] [Cited by in F6Publishing: 61] [Article Influence: 8.9] [Reference Citation Analysis]
34 Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 2004;279:23719-27. [PMID: 15033975 DOI: 10.1074/jbc.M312063200] [Cited by in Crossref: 76] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
35 Glockzin S, von Knethen A, Scheffner M, Brüne B. Activation of the cell death program by nitric oxide involves inhibition of the proteasome. J Biol Chem. 1999;274:19581-19586. [PMID: 10391892 DOI: 10.1074/jbc.274.28.19581] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 3.9] [Reference Citation Analysis]
36 Masdehors P, Merle-Béral H, Magdelénat H, Delic J. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma 2000;38:499-504. [PMID: 10953970 DOI: 10.3109/10428190009059268] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
37 Ramatenki V, Potlapally SR, Dumpati RK, Vadija R, Vuruputuri U. Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer. J Recept Signal Transduct Res 2015;35:536-49. [PMID: 25316404 DOI: 10.3109/10799893.2014.969375] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
38 Ogier-denis E, Codogno P. Autophagy: a barrier or an adaptive response to cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2003;1603:113-28. [DOI: 10.1016/s0304-419x(03)00004-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 85] [Article Influence: 1.7] [Reference Citation Analysis]
39 Bangur CS, Switzer A, Fan L, Marton MJ, Meyer MR, Wang T. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene. 2002;21:3814-3825. [PMID: 12032850 DOI: 10.1038/sj.onc.1205480] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
40 Tallada VA, Daga RR, Palomeque C, Garzón A, Jimenez J. Genome-wide search of Schizosaccharomyces pombe genes causing overexpression-mediated cell cycle defects: New cell cycle regulators in Sz. pombe. Yeast 2002;19:1139-51. [DOI: 10.1002/yea.902] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
41 Gentile M, Bergman Jungeström M, Olsen K, Söderkvist P, Wingren S. p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. European Journal of Cancer 1999;35:1202-7. [DOI: 10.1016/s0959-8049(99)00121-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ogiso Y, Tomida A, Kim H, Tsuruo T. Glucose Starvation and Hypoxia Induce Nuclear Accumulation of Proteasome in Cancer Cells. Biochemical and Biophysical Research Communications 1999;258:448-52. [DOI: 10.1006/bbrc.1999.0635] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
43 Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest. 2002;82:965-980. [PMID: 12177235 DOI: 10.1097/01.LAB.0000022226.23741.37] [Cited by in Crossref: 180] [Cited by in F6Publishing: 53] [Article Influence: 9.5] [Reference Citation Analysis]
44 Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006;3:374-87. [PMID: 16826218 DOI: 10.1038/ncponc0555] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 5.6] [Reference Citation Analysis]
45 Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. Journal of Surgical Research 2003;113:88-95. [DOI: 10.1016/s0022-4804(03)00201-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
46 Cheng LH. Ubiquitin and malignant transformation of oral mucosa. Head Neck 2001;23:972-8. [PMID: 11754502 DOI: 10.1002/hed.1141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Schutte B, Ramaekers FCS. Molecular switches that govern the balance between proliferation and apoptosis. In: Meijer L, Jézéquel A, Ducommun B, editors. Progress in Cell Cycle Research. Boston: Springer US; 2000. pp. 207-17. [DOI: 10.1007/978-1-4615-4253-7_18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
48 Usuba T, Ishibashi Y, Okawa Y, Hirakawa T, Takada K, Ohkawa K. Purification and identification of monoubiquitin-phosphoglycerate mutase B complex from human colorectal cancer tissues. Int J Cancer 2001;94:662-8. [DOI: 10.1002/ijc.1524] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
49 Askari B, Rudbari HA, Micale N, Schirmeister T, Giannetto A, Lanza S, Bruno G, Mirkhani V. Synthesis, solution behaviour and potential anticancer activity of new trinuclear organometallic palladium(II) complex of {S}-1-phenylethyl dithiooxamide: Comparison with the trinuclear heterobimetallic platinum(II) analogue. Polyhedron 2019;164:195-201. [DOI: 10.1016/j.poly.2019.02.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 2005;280:9519-27. [PMID: 15632134 DOI: 10.1074/jbc.M413808200] [Cited by in Crossref: 72] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
51 Ullah K, Zubia E, Narayan M, Yang J, Xu G. Diverse roles of the E2/E3 hybrid enzyme UBE 2O in the regulation of protein ubiquitination, cellular functions, and disease onset. FEBS J 2019;286:2018-34. [DOI: 10.1111/febs.14708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
52 Zerfas BL, Coleman RA, Salazar-Chaparro AF, Macatangay NJ, Trader DJ. Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time. ACS Chem Biol 2020;15:2588-96. [PMID: 32786259 DOI: 10.1021/acschembio.0c00634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
53 Pandiri AR, Sills RC, Ziglioli V, Ton TV, Hong HH, Lahousse SA, Gerrish KE, Auerbach SS, Shockley KR, Bushel PR, Peddada SD, Hoenerhoff MJ. Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer. Toxicol Pathol 2012;40:1141-59. [PMID: 22688403 DOI: 10.1177/0192623312447543] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
54 zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350. [PMID: 12044010 DOI: 10.1038/nrc798] [Cited by in Crossref: 2477] [Cited by in F6Publishing: 2219] [Article Influence: 130.4] [Reference Citation Analysis]
55 Lodén M, Nielsen NH, Roos G, Emdin SO, Landberg G. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene. 1999;18:2557-2566. [PMID: 10353599 DOI: 10.1038/sj.onc.1202488] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 1.4] [Reference Citation Analysis]
56 Vallumsetla N, Paludo J, Kapoor P. Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. Ther Clin Risk Manag 2015;11:1663-74. [PMID: 26609233 DOI: 10.2147/TCRM.S72943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Maaroufi Y, Lacroix M, Lespagnard L, Journé F, Larsimont D, Leclercq G. Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis. Breast Cancer Res 2000;2:444-54. [PMID: 11056692 DOI: 10.1186/bcr92] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
58 Mastoraki A, Ioannidis E, Patsouris E, Safioleas M, Aroni K. PGP 9.5 expression in cutaneous keratoacanthomas and squamous cell carcinomas. Arch Dermatol Res 2009;301:653-8. [DOI: 10.1007/s00403-009-0962-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
59 Cai M, Jin S, Deng L, Zhu L, Hu Z, Liu D, Liu J, Tan M, Gao J, Wang H, Lin B. Lewis y antigen promotes p27 degradation by regulating ubiquitin-proteasome activity. Oncotarget 2017;8:110064-76. [PMID: 29299130 DOI: 10.18632/oncotarget.22617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci. 2000;922:1-10. [PMID: 11193884 DOI: 10.1111/j.1749-6632.2000.tb07020.x] [Cited by in Crossref: 276] [Cited by in F6Publishing: 277] [Article Influence: 13.8] [Reference Citation Analysis]
61 Dou QP, Nam S. Pharmacological proteasome inhibitors and their therapeutic potential. Expert Opinion on Therapeutic Patents 2005;10:1263-72. [DOI: 10.1517/13543776.10.8.1263] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
62 Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9. [PMID: 15659509 DOI: 10.1200/JCO.2005.11.030] [Cited by in Crossref: 406] [Cited by in F6Publishing: 143] [Article Influence: 25.4] [Reference Citation Analysis]
63 Bold RJ, Virudachalam S, Mcconkey DJ. Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome. Journal of Surgical Research 2001;100:11-7. [DOI: 10.1006/jsre.2001.6194] [Cited by in Crossref: 151] [Cited by in F6Publishing: 118] [Article Influence: 7.6] [Reference Citation Analysis]
64 Miyoshi Y, Nakayama S, Torikoshi Y, Tanaka S, Ishihara H, Taguchi T, Tamaki Y, Noguchi S. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Science 2006;97:523-9. [DOI: 10.1111/j.1349-7006.2006.00202.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]
65 Allaman-Pillet N, Størling J, Oberson A, Roduit R, Negri S, Sauser C, Nicod P, Beckmann JS, Schorderet DF, Mandrup-Poulsen T, Bonny C. Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1. J Biol Chem 2003;278:48720-6. [PMID: 14507925 DOI: 10.1074/jbc.M306745200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
66 Petroziello J, Yamane A, Westendorf L, Thompson M, McDonagh C, Cerveny C, Law CL, Wahl A, Carter P. Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer. Oncogene 2004;23:7734-45. [PMID: 15334068 DOI: 10.1038/sj.onc.1207921] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
67 Ghanat Bari M, Ung CY, Zhang C, Zhu S, Li H. Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer Networks. Sci Rep 2017;7:6993. [PMID: 28765560 DOI: 10.1038/s41598-017-07481-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
68 Verlaet M, Deregowski V, Denis G, Humblet C, Stalmans M, Bours V, Castronovo V, Boniver J, Defresne M. Genetic Imbalances in Preleukemic Thymuses. Biochemical and Biophysical Research Communications 2001;283:12-8. [DOI: 10.1006/bbrc.2001.4731] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
69 Rusinek D, Pfeifer A, Cieslicka M, Kowalska M, Pawlaczek A, Krajewska J, Szpak-Ulczok S, Tyszkiewicz T, Halczok M, Czarniecka A, Zembala-Nozynska E, Chekan M, Lamch R, Handkiewicz-Junak D, Ledwon A, Paliczka-Cieslik E, Kropinska A, Jarzab B, Oczko-Wojciechowska M. TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. Cancers (Basel) 2020;12:E1597. [PMID: 32560331 DOI: 10.3390/cancers12061597] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
70 Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, McBride WH, Pajonk F. Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. Transl Oncol 2010;3:50-5. [PMID: 20165695 DOI: 10.1593/tlo.09244] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
71 Uranga J, Hasecke L, Proppe J, Fingerhut J, Mata RA. Theoretical Studies of the Acid-Base Equilibria in a Model Active Site of the Human 20S Proteasome. J Chem Inf Model 2021;61:1942-53. [PMID: 33719420 DOI: 10.1021/acs.jcim.0c01459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Cristillo AD, Nie L, Macri MJ, Bierer BE. Cloning and characterization of N4WBP5A, an inducible, cyclosporine-sensitive, Nedd4-binding protein in human T lymphocytes. J Biol Chem 2003;278:34587-97. [PMID: 12796489 DOI: 10.1074/jbc.M304723200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
73 Gerrero MR, Weber BL. Recent advances in breast cancer biology. Curr Opin Oncol 2001;13:415-9. [PMID: 11673679 DOI: 10.1097/00001622-200111000-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
74 Crinelli R, Bianchi M, Gentilini L, Magnani M, Hiscott J. Activation of the ubiquitin proteolytic system in murine acquired immunodeficiency syndrome affects IkappaBalpha turnover. Eur J Biochem 1999;263:202-11. [PMID: 10429205 DOI: 10.1046/j.1432-1327.1999.00485.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
75 Fiorini M, Ballarò C, Sala G, Falcone G, Alemà S, Segatto O. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 2002;21:6530-9. [PMID: 12226756 DOI: 10.1038/sj.onc.1205823] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 3.3] [Reference Citation Analysis]
76 Legnani FG, Pradilla G, Thai QA, Fiorindi A, Recinos PF, Tyler BM, Gaini SM, DiMeco F, Brem H, Olivi A. Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers. J Neurooncol 2006;77:225-32. [PMID: 16609837 DOI: 10.1007/s11060-005-6937-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
77 von Zeska Kress MR, Harting R, Bayram Ö, Christmann M, Irmer H, Valerius O, Schinke J, Goldman GH, Braus GH. The COP9 signalosome counteracts the accumulation of cullin SCF ubiquitin E3 RING ligases during fungal development. Mol Microbiol 2012;83:1162-77. [PMID: 22329854 DOI: 10.1111/j.1365-2958.2012.07999.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
78 Chan JY, Chang AY, Chan SH. New insights on brain stem death: From bedside to bench. Progress in Neurobiology 2005;77:396-425. [DOI: 10.1016/j.pneurobio.2005.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
79 Whang PG, Gamradt SC, Gates JJ, Lieberman JR. Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate Cancer Prostatic Dis 2005;8:327-34. [DOI: 10.1038/sj.pcan.4500823] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
80 Kashkar H, Deggerich A, Seeger J, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C, Krönke M. NF-κB–independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 2006;109:3982-8. [DOI: 10.1182/blood-2006-10-053959] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
81 Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809-1820. [PMID: 14638851 DOI: 10.1172/jci20039] [Cited by in Crossref: 1368] [Cited by in F6Publishing: 924] [Article Influence: 76.0] [Reference Citation Analysis]
82 Herrero Alvarez N, van de Langemheen H, Brouwer AJ, Liskamp RM. Potential peptidic proteasome inhibitors by incorporation of an electrophilic trap based on amino acid derived α-substituted sulfonyl fluorides. Bioorganic & Medicinal Chemistry 2017;25:5055-63. [DOI: 10.1016/j.bmc.2017.07.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
83 Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, Mayer RJ, Arii S, Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med. 2000;6:96-99. [PMID: 10613832 DOI: 10.1038/71600] [Cited by in Crossref: 217] [Cited by in F6Publishing: 210] [Article Influence: 10.3] [Reference Citation Analysis]
84 Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta. 2012;1825:64-76. [PMID: 22037302 DOI: 10.1016/j.bbcan.2011.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 79] [Article Influence: 3.3] [Reference Citation Analysis]
85 Geetha T, Vishwaprakash N, Sycheva M, Babu JR. Sequestosome 1/p62: across diseases. Biomarkers 2012;17:99-103. [PMID: 22296116 DOI: 10.3109/1354750X.2011.653986] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
86 Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809-1820. [PMID: 14638851 DOI: 10.1172/jci200320039] [Cited by in Crossref: 149] [Cited by in F6Publishing: 3] [Article Influence: 8.3] [Reference Citation Analysis]
87 Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Nakata Y, Kuma K, Amino N. PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. European Journal of Cancer 2004;40:614-8. [DOI: 10.1016/j.ejca.2003.11.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
88 Darrasse-Jèze G, Podsypanina K. How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol 2013;4:292. [PMID: 24133490 DOI: 10.3389/fimmu.2013.00292] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
89 Paoluzzi L, O'Connor OA. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 2006;20:13-23. [PMID: 16573348 DOI: 10.2165/00063030-200620010-00002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
90 Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D, Schoonmaker JA, Mulay S, Ayers DC, Bouxsein ML, Stein GS, Mukherjee S, Lian JB. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 2010;16:4978-89. [PMID: 20843837 DOI: 10.1158/1078-0432.CCR-09-3293] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
91 Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002;16:433-443. [PMID: 11960320 DOI: 10.1038/sj.leu.2402417] [Cited by in Crossref: 358] [Cited by in F6Publishing: 329] [Article Influence: 18.8] [Reference Citation Analysis]
92 Adams J, Elliott PJ. New agents in cancer clinical trials. Oncogene 2000;19:6687-92. [PMID: 11426656 DOI: 10.1038/sj.onc.1204088] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
93 Min L, Xu H, Wang J, Qu L, Jiang B, Zeng Y, Meng L, Jin H, Shou C. N-α-acetyltransferase 10 protein is a negative regulator of 28S proteasome through interaction with PA28β. FEBS Lett 2013;587:1630-7. [PMID: 23624078 DOI: 10.1016/j.febslet.2013.04.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
94 Valiya Veettil M, Krishna G, Roy A, Ghosh A, Dutta D, Kumar B, Chakraborty S, Anju TR, Sharma-Walia N, Chandran B. Kaposi's Sarcoma-Associated Herpesvirus Infection Induces the Expression of Neuroendocrine Genes in Endothelial Cells. J Virol 2020;94:e01692-19. [PMID: 31969437 DOI: 10.1128/JVI.01692-19] [Reference Citation Analysis]
95 Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 1999;155:711-5. [PMID: 10487828 DOI: 10.1016/S0002-9440(10)65169-3] [Cited by in Crossref: 112] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
96 Rosenzweig R, Glickman M. Chaperone-driven proteasome assembly. Biochemical Society Transactions 2008;36:807-12. [DOI: 10.1042/bst0360807] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
97 Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13-23. [PMID: 16292537 DOI: 10.1007/s00280-005-0135-z] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
98 Cecarini V, Bonfili L, Cuccioloni M, Mozzicafreddo M, Angeletti M, Keller JN, Eleuteri AM. The fine-tuning of proteolytic pathways in Alzheimer's disease. Cell Mol Life Sci 2016;73:3433-51. [PMID: 27120560 DOI: 10.1007/s00018-016-2238-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
99 Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000;18:109-121. [PMID: 10857991 DOI: 10.1023/a: 1006321828515] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006;20:1341-52. [DOI: 10.1038/sj.leu.2404278] [Cited by in Crossref: 94] [Cited by in F6Publishing: 74] [Article Influence: 6.3] [Reference Citation Analysis]
101 Zhang Y, Jones C, Dickman M. Identification of differentially expressed genes following treatment of monkey kidney cells with the mycotoxin fumonisin B1. Food and Chemical Toxicology 2001;39:45-53. [DOI: 10.1016/s0278-6915(00)00114-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
102 Cohen EE. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Seminars in Oncology 2004;31:755-68. [DOI: 10.1053/j.seminoncol.2004.09.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
103 Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 1999;35:2010-30. [PMID: 10711243 DOI: 10.1016/s0959-8049(99)00280-4] [Cited by in Crossref: 98] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
104 Torelli GF, Paolini R, Tatarelli C, Soriani A, Vitale A, Guarini A, Santoni A, Foa R. Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia. Br J Haematol 2003;120:201-8. [PMID: 12542476 DOI: 10.1046/j.1365-2141.2003.04044.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
105 Glickman MH, Maytal V. Regulating the 26S proteasome. Curr Top Microbiol Immunol 2002;268:43-72. [PMID: 12083008 DOI: 10.1007/978-3-642-59414-4_3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
106 Tian ZH, Li ZF, Zhou SB, Liang YY, He DC, Wang DS. Differentially expressed proteins of MCF-7 human breast cancer cells affected by Zilongjin, a complementary Chinese herbal medicine. Proteomics Clin Appl 2010;4:550-9. [PMID: 21137072 DOI: 10.1002/prca.200900092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Zhang X, Frezza M, Milacic V, Ronconi L, Fan Y, Bi C, Fregona D, Dou QP. Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. J Cell Biochem 2010;109:162-72. [PMID: 19911377 DOI: 10.1002/jcb.22394] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 8.2] [Reference Citation Analysis]
108 Yuan F, Lu J, You P, Yang Z, Yang P, Ma Q, Tao T. Proteomic profiling of expression of proteasomal subunits from livers of mice treated with diethylnitrosamine. Proteomics 2013;13:389-97. [DOI: 10.1002/pmic.201200288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
109 Wójcik C. Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target. Emerging Therapeutic Targets 2005;4:89-111. [DOI: 10.1517/14728222.4.1.89] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
110 Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H, Hatayama T, Hatada S, Tsujioka T, Sato Y. Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol. 2004;127:292-298. [PMID: 15491288 DOI: 10.1111/j.1365-2141.2004.05205.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
111 Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA, Sutherland GR, Callen DF, Kremmidiotis G. Sequencing, Transcript Identification, and Quantitative Gene Expression Profiling in the Breast Cancer Loss of Heterozygosity Region 16q24.3 Reveal Three Potential Tumor-Suppressor Genes. Genomics 2002;80:303-10. [DOI: 10.1006/geno.2002.6828] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
112 Milacic V, Chen D, Giovagnini L, Diez A, Fregona D, Dou QP. Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol Appl Pharmacol 2008;231:24-33. [PMID: 18501397 DOI: 10.1016/j.taap.2008.03.009] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
113 Wang J, Wang N, Zhao WD, Zhao LX, Jing YG, Yang LJ, He J, Li J. RNA-Seq Analysis Identified XLOC_009190 as Potential Therapeutic Target for Lung Adenocarcinoma. Onco Targets Ther 2019;12:11221-9. [PMID: 31908488 DOI: 10.2147/OTT.S225532] [Reference Citation Analysis]
114 Zilfou JT, Hoffman WH, Sank M, George DL, Murphy M. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol 2001;21:3974-85. [PMID: 11359905 DOI: 10.1128/MCB.21.12.3974-3985.2001] [Cited by in Crossref: 85] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
115 Xu G, Jaffrey SR. Proteomic identification of protein ubiquitination events. Biotechnol Genet Eng Rev 2013;29:73-109. [PMID: 24568254 DOI: 10.1080/02648725.2013.801232] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
116 Hamilton MH, Tcherepanova I, Huibregtse JM, McDonnell DP. Nuclear import/export of hRPF1/Nedd4 regulates the ubiquitin-dependent degradation of its nuclear substrates. J Biol Chem 2001;276:26324-31. [PMID: 11342538 DOI: 10.1074/jbc.M101205200] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
117 Furfaro AL, Piras S, Domenicotti C, Fenoglio D, De Luigi A, Salmona M, Moretta L, Marinari UM, Pronzato MA, Traverso N, Nitti M. Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib. PLoS One 2016;11:e0152465. [PMID: 27023064 DOI: 10.1371/journal.pone.0152465] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
118 Lee YM, Lee JY, Kim MJ, Bae HI, Park JY, Kim SG, Kim DS. Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci 2006;97:1205-10. [PMID: 16965602 DOI: 10.1111/j.1349-7006.2006.00320.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
119 Ishiwata S, Ozawa Y, Katayama J, Kaneko S, Shindo H, Tomioka Y, Ishiwata T, Asano G, Ikegawa S, Mizugaki M. Elevated expression level of 60-kDa subunit of tRNA-guanine transglycosylase in colon cancer. Cancer Lett 2004;212:113-9. [PMID: 15246567 DOI: 10.1016/j.canlet.2004.03.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
120 Hamouda MA, Belhacene N, Puissant A, Colosetti P, Robert G, Jacquel A, Mari B, Auberger P, Luciano F. The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. Oncotarget 2014;5:6252-66. [PMID: 25051369 DOI: 10.18632/oncotarget.2193] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
121 Margareto J, Leis O, Larrarte E, Idoate MA, Carrasco A, Lafuente JV. Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways. J Mol Neurosci 2007;32:53-63. [PMID: 17873288 DOI: 10.1007/s12031-007-0008-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
122 Xiong X, Wang Y, Liu C, Lu Q, Liu T, Chen G, Rao H, Luo S. Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. Exp Cell Res 2014;326:78-89. [PMID: 24880126 DOI: 10.1016/j.yexcr.2014.05.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
123 Turner K. Inherited renal cancer: INHERITED RENAL CANCER. BJU International 2000;86:155-64. [DOI: 10.1046/j.1464-410x.2000.00702.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2002; 8(4): 638-643 [PMID: 12174370 DOI: 10.3748/wjg.v8.i4.638] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 57] [Article Influence: 3.3] [Reference Citation Analysis]
125 Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000;18:109-21. [PMID: 10857991 DOI: 10.1023/a:1006321828515] [Cited by in Crossref: 187] [Cited by in F6Publishing: 41] [Article Influence: 8.9] [Reference Citation Analysis]
126 Masdehors P, Merle-béral H, Maloum K, Ömura S, Magdelénat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000;96:269-74. [DOI: 10.1182/blood.v96.1.269] [Cited by in Crossref: 66] [Article Influence: 3.1] [Reference Citation Analysis]
127 Tóth S, Vastagh C, Réz G, Pálfia Z. UBIQUITIN CYTOCHEMICAL CHANGES DURING AZASERINE-INITIATED PANCREATIC CARCINOGENESIS. Acta Biologica Hungarica 2001;52:383-91. [DOI: 10.1556/abiol.52.2001.4.3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R, Allday MJ, Xiao ZX. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 2005;20:699-708. [PMID: 16337594 DOI: 10.1016/j.molcel.2005.10.017] [Cited by in Crossref: 169] [Cited by in F6Publishing: 170] [Article Influence: 11.3] [Reference Citation Analysis]
129 Thompson HG, Harris JW, Wold BJ, Lin F, Brody JP. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 2003;22:2322-33. [PMID: 12700667 DOI: 10.1038/sj.onc.1206325] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 6.8] [Reference Citation Analysis]
130 de Araujo CB, Russo LC, Castro LM, Forti FL, do Monte ER, Rioli V, Gozzo FC, Colquhoun A, Ferro ES. A novel intracellular peptide derived from g1/s cyclin d2 induces cell death. J Biol Chem 2014;289:16711-26. [PMID: 24764300 DOI: 10.1074/jbc.M113.537118] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
131 Seliger B, Handke D, Schabel E, Bukur J, Lichtenfels R, Dammann R. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. J Transl Med. 2009;7:90. [PMID: 19857250 DOI: 10.1186/1479-5876-7-90] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
132 Qin JM, Fu XY, Li SJ, Liu SQ, Zeng JZ, Qiu XH, Wu MC, Wang HY. Gene and protein expressions of p28GANK in rat with liver regeneration. World J Gastroenterol 2003; 9(11): 2523-2527 [PMID: 14606089 DOI: 10.3748/wjg.v9.i11.2523] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
133 Askari B, Rudbari HA, Micale N, Schirmeister T, Maugeri A, Navarra M. Anticancer study of heterobimetallic platinum(II)-ruthenium(II) and platinum(II)-rhodium(III) complexes with bridging dithiooxamide ligand. Journal of Organometallic Chemistry 2019;900:120918. [DOI: 10.1016/j.jorganchem.2019.120918] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]